BIOMAT Database Logo BIOMAT Database Logo

Salvage therapy for recurrent and refractory ovarian cancer with high-dose chemotherapy and autologous bone marrow support: a Gynecologic Oncology Group pilot study. 1994

E R Broun, and J L Belinson, and J S Berek, and D McIntosh, and D Hurd, and H Ball, and S Williams
Indiana University/Indiana Regional Cancer Center, Bone Marrow Transplant Unit, Indianapolis.

Nine patients with recurrent or refractory epithelial ovarian carcinoma following previous chemotherapy were treated with high-dose carboplatin (300 mg/m2) and ifosfamide according to a dose escalation schedule (1.50, 1.75, 2.00 g/m2), each given intravenously daily for 5 days with autologous bone marrow support. Eight of the nine patients were evaluable for response. Five achieved complete response (CR), all of whom relapsed at 4, 5, 6, 8, and 23 months following treatment. Two partial responses persisted for 6 months, and one patient with stable disease progressed after 2 months and has since died of disease. The median duration of remission was 6 months. The treatment was well tolerated across the doses of ifosfamide with the exception of one treatment-related death which was due to acute renal failure and central nervous system toxicity from ifosfamide. It appears that the use of high-dose chemotherapy with autologous bone marrow support in the treatment of ovarian cancer produced a high rate of response of short duration in this small group of heavily pretreated women.

UI MeSH Term Description Entries
D007069 Ifosfamide Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Isofosfamide,Isophosphamide,Asta Z 4942,Holoxan,Iphosphamide,Iso-Endoxan,NSC-109,724,NSC-109724,Iso Endoxan,NSC 109,724,NSC 109724,NSC109,724,NSC109724
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

E R Broun, and J L Belinson, and J S Berek, and D McIntosh, and D Hurd, and H Ball, and S Williams
Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support.
March 1994, Cancer,
E R Broun, and J L Belinson, and J S Berek, and D McIntosh, and D Hurd, and H Ball, and S Williams
High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer.
April 1989, European journal of cancer & clinical oncology,
E R Broun, and J L Belinson, and J S Berek, and D McIntosh, and D Hurd, and H Ball, and S Williams
High-dose chemotherapy and autologous bone marrow support for breast cancer.
January 1991, Important advances in oncology,
E R Broun, and J L Belinson, and J S Berek, and D McIntosh, and D Hurd, and H Ball, and S Williams
High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study.
February 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
E R Broun, and J L Belinson, and J S Berek, and D McIntosh, and D Hurd, and H Ball, and S Williams
Effective high-dose chemotherapy with autologous bone marrow infusion in resistant ovarian cancer.
March 1984, Gynecologic oncology,
E R Broun, and J L Belinson, and J S Berek, and D McIntosh, and D Hurd, and H Ball, and S Williams
[High dose chemotherapy with autologous bone marrow transplantation in ovarian adenocarcinoma].
February 1993, Bulletin du cancer,
E R Broun, and J L Belinson, and J S Berek, and D McIntosh, and D Hurd, and H Ball, and S Williams
High-dose chemotherapy with autologous stem cell support as salvage therapy in recurrent gestational trophoblastic disease.
September 2013, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
E R Broun, and J L Belinson, and J S Berek, and D McIntosh, and D Hurd, and H Ball, and S Williams
Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study.
August 1993, Gynecologic oncology,
E R Broun, and J L Belinson, and J S Berek, and D McIntosh, and D Hurd, and H Ball, and S Williams
High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer.
November 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
E R Broun, and J L Belinson, and J S Berek, and D McIntosh, and D Hurd, and H Ball, and S Williams
Future strategies for the treatment of advanced epithelial ovarian cancer using high-dose chemotherapy and autologous bone marrow support.
September 1994, Gynecologic oncology,
Copied contents to your clipboard!